{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:58:17Z","timestamp":1790074697773,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5720-3","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:02:59Z","timestamp":1562155379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study"],"prefix":"10.1186","volume":"19","author":[{"given":"Hiroyuki","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Minashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"5720_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: cancer incidence and mortality worldwide. \n                    http:\/\/gco.iarc.fr\/\n                    \n                  ."},{"key":"5720_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"5720_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"5720_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u20138.","journal-title":"Ann Oncol"},{"key":"5720_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10120-003-0243-6","volume":"6","author":"T Fujimura","year":"2003","unstructured":"Fujimura T, Ishii K, Oyama K, et al. A new scoring system for peritoneal metastasis in gastric cancer. Gastric Cancer. 2003;6:146\u201352.","journal-title":"Gastric Cancer"},{"key":"5720_CR6","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","volume":"22","author":"J Wei","year":"2016","unstructured":"Wei J, Wu ND, Liu BR. Regional but fatal: intraperitoneal metastasis in gastric cancer. World J Gastroenterol. 2016;22:7478\u201385.","journal-title":"World J Gastroenterol"},{"key":"5720_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063\u20139.","journal-title":"Lancet Oncol"},{"key":"5720_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jjco\/hyt114","volume":"43","author":"K Shirao","year":"2013","unstructured":"Shirao K, Boku N, Yamada Y, et al. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43:972\u201380.","journal-title":"Jpn J Clin Oncol"},{"key":"5720_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10120-011-0056-y","volume":"15","author":"S Iwasa","year":"2012","unstructured":"Iwasa S, Nakajima TE, Nakamura K, et al. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer. 2012;15:21\u20136.","journal-title":"Gastric Cancer"},{"key":"5720_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10147-017-1198-7","volume":"23","author":"H Hara","year":"2018","unstructured":"Hara H, Kadowaki S, Asayama M, et al. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. Int J Clin Oncol. 2018;23:275\u201380.","journal-title":"Int J Clin Oncol"},{"key":"5720_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10120-012-0143-8","volume":"16","author":"K Shitara","year":"2013","unstructured":"Shitara K, Mizota A, Matsuo K, et al. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16:48\u201355.","journal-title":"Gastric Cancer"},{"key":"5720_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"5720_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1359-6349(09)71231-5","volume":"7","author":"A Sawaki","year":"2009","unstructured":"Sawaki A, Yamaguchi K, Nabeya Y, et al. 5-FU\/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial (ISO-5FU10 study group trial). Eur J Cancer Suppl. 2009;7:363.","journal-title":"Eur J Cancer Suppl"},{"key":"5720_CR14","first-page":"7037","volume":"37","author":"T Masuishi","year":"2017","unstructured":"Masuishi T, Kadowaki S, Kondo M, et al. FOLFOX as first-line therapy for gastric Cancer with severe peritoneal metastasis. Anticancer Res. 2017;37:7037\u201342.","journal-title":"Anticancer Res"},{"key":"5720_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37\u201341.","journal-title":"Cancer"},{"key":"5720_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587\u201391.","journal-title":"Br J Cancer"},{"key":"5720_CR17","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u201329.","journal-title":"J Clin Oncol."},{"key":"5720_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10120-015-0542-8","volume":"19","author":"T Nishina","year":"2016","unstructured":"Nishina T, Boku N, Gotoh M, et al. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Gastric Cancer. 2016;19:902\u201310.","journal-title":"Gastric Cancer"},{"key":"5720_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jjco\/hys111","volume":"42","author":"S Iwasa","year":"2012","unstructured":"Iwasa S, Goto M, Yasui H, et al. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. Jpn J Clin Oncol. 2012;42:787\u201393.","journal-title":"Jpn J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5720-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T23:33:22Z","timestamp":1593646402000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5720-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5720"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5720-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,3]]},"assertion":[{"value":"28 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by Institutional Review Board (Ethics Committee, St. Marianna University School of Medicine) in accordance with the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. Written informed consent was obtained from all patients before treatment initiation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"652"}}